Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

595 results about "Prostatic Cancers" patented technology

Multi-mode prostate cancer biochemical recurrence risk layered prediction system based on artificial intelligence

The invention provides a multi-mode prostate cancer biochemical recurrence risk layering prediction system based on artificial intelligence. Based on an Xgboost framework, a postoperative patient pathological panoramic pathological section scanning image is analyzed through end-to-end, multi-scale, multi-center and large-sample analysis, pathological information is utilized to the maximum extent, meanwhile, the prognosis risk of a patient can be evaluated more comprehensively in combination with clinical indexes such as CAPRA-S scores, and the method has obvious advantages compared with a traditional model. The method aims at better fitting the use scene of a hospital, the risk of prostate cancer recurrence of a patient is more efficiently and accurately predicted by fusing pathological section features and clinical features after a radical operation, and the risk of recurrence of the patient within 3 years and longer time after the radical operation can be accurately predicted. And an interpretable module is further combined to assist a doctor to interpret a result, so that precise layering and personalized follow-up visit of the BCR risk of the prostatic cancer patient are realized, the risk of excessive treatment and missed diagnosis is reduced, and the method has a good application prospect.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Targeted treatment of prostate cancers and other tumors by an antibody-drug conjugate

Provided herein is an antibody-drug conjugate with a side chain linker containing an affinity ligand for enhancement of targeted treatment of prostate cancers and other tumors. It also relates to preparation of such conjugate, pharmaceutical compositions, and methods in treatment of cancers.
Owner:HANGZHOU SEEHE BIOTECHNOLOGY CO LTD +2

Treatment of prostate cancer

Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof, and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.
Owner:TAKEDA PHARMA CO LTD +1

Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers

The present invention provides methods of screening for compounds that interfere with the interaction between ERG. ETV1, ETV4 or ETV5 and mSWI / SNF (BAF) chromatin remodeling complex proteins. Included are methods of screening for compounds that interfere with the interaction between ERG, ETV1, ETV4 or ETV5 and BAF155. Methods of treating prostate cancer with compounds that interfere with the interaction between ERG, ETV1, ETV4 or ETV5 and mSWI / SNF (BAF) chromatin remodeling complex proteins are also provided.
Owner:DANA FARBER CANCER INSTITUTE INC

Treatment of prostate cancer

Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof, and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.
Owner:TAKEDA PHARMA CO LTD +1

Prostate cancer biochemical recurrence prediction system based on deep learning image and clinical information multi-mode model

The invention provides a prostate cancer biochemical recurrence prediction system based on a deep learning image and clinical information multi-mode model. The prostate cancer biochemical recurrence prediction system comprises an input module, a preprocessing module, a feature selection module, a fusion module, a prediction module, a data management and storage module and a result output and decision support module. According to the method, bpMRI image data and clinical information of a patient are fully utilized, multi-mode information is fully fused through a deep learning technology, and accurate prediction of biochemical recurrence is achieved. And the robustness of the model is further enhanced by adopting 5-fold cross validation and a diversified data enhancement strategy. Experimental results show that the method can assist in making more accurate patient layering and personalized follow-up visit schemes, and potentially reduces the over-treatment and missed diagnosis risks. The invention provides an efficient and reliable AI solution for prostatic cancer prognosis evaluation, and provides powerful support for promoting precise medical treatment and making personalized treatment strategies.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Plasma exosome long-chain RNA marker combination for clinical diagnosis of prostatic cancer, kit and application

PendingCN118957081AComprehensively reflect biological characteristicsreduce medical burdenMicrobiological testing/measurementDNA/RNA fragmentationMedical diagnosisTherapeutic effect
The invention discloses a marker for clinical diagnosis of prostate cancer, a kit and application, and belongs to the technical field of medical diagnosis. The marker disclosed by the invention can more comprehensively reflect biological characteristics of prostatic cancer by combining expression or variation conditions of a plurality of genes, so that the diagnosis accuracy is improved; as the prostate cancer possibly has no obvious symptoms in the early stage, the high-sensitivity marker can help doctors to find the prostate cancer in the early stage, so that the treatment effect and the survival rate of patients are improved; according to the kit and the system based on the marker, the detection information of the marker is obtained, a set threshold value is combined, the prostatic cancer of a subject is diagnosed or predicted, a large amount of data can be efficiently processed, an accurate diagnosis result can be provided, diagnosis and treatment of the prostatic cancer are facilitated, and the detection accuracy of the prostatic cancer is improved. A new clue can be provided for pathogenesis and prevention of prostatic cancer, and the prostatic cancer vaccine has a wide market prospect.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY

Preparation method and application of SERS (Surface Enhanced Raman Scattering) substrate with sunken structure for prostatic cancer exosome detection

The invention discloses a preparation method and application of a concave-structure SERS (Surface Enhanced Raman Scattering) substrate for prostatic cancer exosome detection, and relates to the field of Raman spectrum detection. The invention aims to solve the problems that the quantity of electromagnetic field hot spots of the currently reported SERS substrate with the concave structure is small, the SERS substrate does not have good uniformity, the size is not matched with EVs, the detected EVs signal is relatively weak, and the parting detection requirement cannot be met. The preparation method of the SERS substrate with the concave structure comprises the following steps: 1, preparing a PDMS concave trap structure array; 2, preparing a concave well array of which the surface is covered with densely arranged Au NPs; according to the invention, Au nanoparticles are grown in situ in a PDMS concave structure, a concave trap array of which the size is matched with that of EVs and the surface is covered with densely arranged Au NPs is constructed, high-sensitivity detection (lower detection limit of 105 particles / mL) and high-accuracy typing of prostatic cancer EVs are realized, and the accuracy rate can reach 98% or more.
Owner:HARBIN INST OF TECH

Substituted oxadiazole compound as well as preparation method and application thereof

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a series of substituted oxadiazole compounds as well as a preparation method and application thereof. Pharmacological tests show that the series of compounds have strong selectivity and inhibition effect on SphK2, and have anti-proliferation effect on cervical cancer cells, prostate cancer cells and colon cancer cells.
Owner:SHANDONG FIRST MEDICAL UNIV & SHANDONG ACADEMY OF MEDICAL SCI

Gleason grading method and device for prostatic cancer pathological image, equipment and medium

PendingCN120088201AImage enhancementImage analysisFeature vectorGleason grade
The embodiment of the invention provides a Grignson grading method and device for a prostate cancer pathological image, equipment and a medium. The method comprises the following steps: acquiring a prostate cancer pathological image which is a full-view digital slice image; dividing a non-blank area of the prostatic cancer pathological image into a plurality of non-overlapping examples; converting the instance into a high-dimensional feature vector; the high-dimensional feature vector is input to a pre-trained multi-branch hybrid supervised network model, slice-level representation is obtained, the multi-branch hybrid supervised network model comprises an attention backbone network, instance-level branches and slice-level branches, the slice-level branches comprise slice-level benign branches and slice-level malignant branches, and slice-level representation is obtained; the slice-level malignant branch comprises an instance compression module and a component extraction module; and inputting the slice level representation into a classifier to obtain a Grignson classification result of the prostatic cancer pathological image. Based on this, the embodiment of the invention can improve the accuracy of Gleason grading of the prostatic cancer pathological image.
Owner:WUYI UNIV

Compositions and methods for detection of prostate cancer

The present disclosure in one aspect provides technologies for detection of prostate cancer, e.g., early detection of prostate cancer. In another aspect, technologies provided herein are useful for selecting and / or monitoring and / or evaluating efficacy of, a treatment administered to a subject determined to have or susceptible to prostate cancer. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by measuring tumor burdens and changes in tumor burdens in conjunction with therapeutics. In some embodiments, technologies provided herein are useful for development of companion diagnostics, e.g., by identifying biomarkers in subjects' bodily fluid samples (e.g., blood samples) that are associated with therapeutic response.
Owner:MERCY BIOANALYTICS INC

Prostate cancer diagnosis method based on multimodal large model prompt learning mechanism

ActiveCN120954689AMedical automated diagnosisBiological modelsProstate ultrasoundRadiology
The invention belongs to the field of characterization learning, and particularly relates to a prostate cancer diagnosis method based on a multimodal large model prompt learning mechanism. Comprising the following steps: step 1, data preprocessing; 2, key frames and similarity are calculated, and irrelevant editing is compressed; step 3, text and image alignment training; step 4, a test stage; according to the method, a similarity-based screening mechanism is provided, ultrasonic videos under coarse-grained labels are preliminarily screened under segmentation of a large model, and focus areas are focused on in time sequence; meanwhile, a pre-processing mechanism based on a large model is provided, and the influence of a large amount of irrelevant information existing in prostate ultrasonic image scanning on the model is compressed at a data end, so that the diagnosis effect of the model is improved.
Owner:SHANGHAI TENTH PEOPLES HOSPITAL +1

Gleason grading method and device for prostatic cancer pathological image, equipment and medium

The embodiment of the invention provides a Grignson grading method and device for a prostate cancer pathological image, equipment and a medium. The method comprises the following steps: acquiring a prostate cancer pathological image which is a full-view digital slice image; performing feature extraction on the prostate cancer image to obtain pathological image features; the pathological image features are input into a multi-instance learning model based on time-frequency interaction to obtain fusion features, the multi-instance learning model based on time-frequency interaction comprises a feature reconstruction module and a time-frequency feature interaction module, the feature reconstruction module is used for extracting high-frequency feature information and low-frequency feature information from the pathological image features, and the time-frequency feature interaction module is used for interacting with the high-frequency feature information and the low-frequency feature information; the time-frequency feature interaction module is used for extracting time-domain feature information and frequency-domain feature information from pathological image features; and inputting the fusion features into a classifier to obtain a Grignson classification result of the prostatic cancer pathological image. Based on this, the embodiment of the invention can improve the accuracy of Gleason grading of the prostatic cancer pathological image.
Owner:WUYI UNIV

Compounds and methods for the targeted degradation of androgen receptor

This disclosure pertains to methods of treating prostate cancer in a subject in need thereof, including, for example, metastatic prostate cancer, castrate-resistant prostate cancer, and metastatic castrate-resistant prostate cancer, wherein the method comprises administering to the subject a therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, and further comprises a step of discontinuing or reducing the administration of a CYP3A inhibitor or inducer, an efflux transporter substrate or inhibitor, or an uptake transporter substrate or inhibitor, to the subject prior to initiating administration of Compound Aor the pharmaceutically acceptable salt thereof.
Owner:ARVINAS OPERATIONS INC

Application of protein in small extracellular vesicles as prostate cancer diagnostic marker

ActiveCN119125561AHigh AUC valueHigh specificity and sensitivityMaterial analysisAntigenPsa antigen
The invention discloses application of small extracellular endovesicular protein as a prostatic cancer diagnostic marker, and is characterized in that the small extracellular endovesicular protein is plasma sample sEV protein LAMB1 and / or urine sample sEV protein Histone H4, and the plasma sample sEV protein LAMB1 is applied as a metastatic prostatic cancer diagnostic marker. The sEV protein LAMB1 of the plasma sample is combined with a prostate specific antigen to serve as metastatic prostate cancer; the application of the sEV protein Histone H4 in the urine sample as a prostate cancer grading diagnosis marker, the application of the sEV protein Histone H4 in the urine sample as a high-risk prostate cancer diagnosis marker and the application of the combination of the sEV protein Histone H4 in the urine sample and a prostate specific antigen as the high-risk prostate cancer diagnosis marker have the advantages of high sensitivity and strong specificity.
Owner:NINGBO FIRST HOSPITAL

Radiopharmaceutical labeled precursor targeting prostate specific membrane antigen, fluorine radiolabeled compound thereof and application of fluorine radiolabeled compound

The invention discloses a class of radiopharmaceutical labeled precursors targeting prostate specific membrane antigens, the structure of the radiopharmaceutical labeled precursors is shown as the following: # imgabs0 #, a precursor reagent RESCA-PSMA-1802 targeting prostate specific membrane antigens is synthesized for the first time, the reagent can be labeled by using an 18F-Al method to prepare a positron imaging agent 18FAl-RESCA-PSMA-1802, and the reagent can be used for preparing the prostate specific membrane antigens. The polymer has good stability and biological activity in vivo and in vitro, has good targeting property on prostate cancer cells, can reflect tumor recurrence or metastasis conditions, and is very suitable for PET imaging.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Prostate cancer tissue HE virtual staining algorithm based on deep learning

The invention relates to a prostate cancer tissue Hamp based on deep learning; the invention discloses an E virtual staining algorithm, and belongs to the field of malignant tumors. The method comprises the following steps: 1, obtaining a prostate cancer tissue slice white piece and a corresponding Hamp; e, an image data set; 2, performing data preprocessing on the data set; 3, inputting the preprocessed standard data set into the model for training; step 4, inputting the data set into a designed Attention-CycleGAN network, after inputting a source domain image, outputting a conversion image of a target domain by the model, and training a prostatic cancer tissue Hamp; and E, virtualizing the dyeing model. The prostate cancer tissue Hamp based on deep learning; according to the E virtual dyeing algorithm, the model is more excellent in performance when processing a complex image conversion task, the generated image is more vivid and meticulous, the discriminator extracts the multi-scale features of the input image through the multilayer convolutional network, and the authenticity of the input image can be more accurately judged in combination with the enhancement characteristic of the space attention mechanism, so that the image conversion efficiency is improved. Therefore, the precision of the whole model is improved.
Owner:SHANGHAI UNIV +1

METHOD OF DETECTING PROSTATE CANCER IN A HUMAN SUBJECT USING A Cu 64 PSMA I&T INJECTION

The present disclosure provides a method of detecting prostate cancer in a human subject wherein the human subject is administrated about 7 mCi to about 9 mCi of a Cu-64 PSMA I&T composition, images are obtained between 1 and 4 hours post administration, and wherein the images obtained retain acceptable image quality up to 4 hours post dose.
Owner:CURIUM US LLC

Prostate cancer focus accurate positioning method based on fusion navigation technology

The invention provides a prostate cancer focus accurate positioning method based on a fusion navigation technology, and relates to the technical field of data processing, and the method comprises the steps: collecting a plurality of prostate images; selecting a control point from the prostate image in combination with a sparse regularization algorithm; determining an optimal deformation field according to the control points, and performing elastic registration on the prostate image based on the optimal deformation field; differential multi-resolution fusion is carried out on the registered prostate images, and a prostate three-dimensional model is reconstructed; constructing a lesion dynamic extraction model comprising a three-dimensional convolutional network, a pooling layer, an interested layer and a bounding box regression layer which are connected in sequence; a loss function of the focus dynamic extraction model is established, and the loss function comprises an intersection-to-union ratio loss item and a distributed focus loss item; under the supervision of the loss function, training the focus dynamic extraction model; and positioning a lesion point in the prostate three-dimensional model through the trained lesion dynamic extraction model. And the focus point positioning speed and accuracy are improved.
Owner:THE SECOND HOSPITAL OF TIANJIN MEDICAL UNIV

Deep learning technique for automated radiological image analysis and disease detection

A real-time artificial intelligence (AI) framework is provided for the automated analysis of radiological images and detection of disease, such as extracapsular extension (ECE) in prostate cancer. The system includes a dual deep learning architecture comprising a first convolutional neural network (CNN) for identifying diagnostically relevant image slices from three-dimensional MRI data, and a second CNN for classifying disease presence based on those slices. A preprocessing pipeline standardizes and harmonizes image input, and cropping algorithms isolate the region of interest for enhanced model performance. This framework enables scalable, high-accuracy diagnosis across various imaging modalities including but not limited to MRI, CT, PET, ultrasound, and diverse disease types, improving clinical decision-making and supporting integration into real-time radiology workflows.
Owner:RES FOUND THE CITY UNIV OF NEW YORK

Treatment of prostate cancer

Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof. Another method includes: administering once-daily to the subject in need thereof, an oral load dose formulation having from 240 mg to 480 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof, and thereafter administering once-daily to the subject, an oral maintenance dose formulation having 80 mg to 160 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N′-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.
Owner:TAKEDA PHARMA CO LTD +1

Cyclophosphamide ternary nano-micelle and preparation method thereof

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a cyclophosphamide ternary nano-micelle and a preparation method thereof.The cyclophosphamide ternary nano-micelle prepared through the method can be used for treating malignant lymphoma, multiple myeloma, leukemia, breast cancer, ovarian cancer, cervical cancer, prostatic cancer, colon cancer, bronchial cancer, lung cancer and the like. Reasonable preparation steps and a preparation formula are adopted, the use of an organic reagent is reduced, the irritation of cyclophosphamide is reduced and the stability of the micelle is improved by adjusting a freeze-drying technology, and the cyclophosphamide micelle adopts amphiphilic macromolecules as a carrier material, so that the drug loading capacity and the stability of the micelle are obviously improved, and the bioavailability of the micelle is improved. The ternary nano-micelle system has the advantages that the solubility of cyclophosphamide is improved, the in-vivo bioavailability is increased, the preparation method is simple, the micelle performance is stable, and large-scale industrial production is facilitated.
Owner:HUZHOU ARTHUR PHARM CO LTD

Out-of-distribution detection for artificial intelligence systems for prostate cancer detection

Systems and methods for determining whether input medical images are out-of-distribution of training images on which a machine learning based medical imaging analysis network is trained are provided. One or more input medical images of a patient are received. One or more reconstructed images of the one or more input medical images are generated using a machine learning based reconstruction network. It is determined whether the one or more input medical images are out-of-distribution from training images on which a machine learning based medical imaging analysis network is trained based on the one or more input medical images and the one or more reconstructed images. The determination of whether the one or more input medical images are out-of-distribution from the training images is output.
Owner:SIEMENS HEALTHINEERS AG

Application of atypical retinoid A-7 in preparation of androgen receptor inhibitor and antitumor drug

The invention discloses application of atypical retinoid A-7 in preparation of androgen receptor inhibitors and antitumor drugs, and belongs to the technical field of medicines. It is proved for the first time that AR can be degraded through a CMA pathway, and the atypical retinoid A-7 serving as an AR inhibitor can obviously reduce the AR protein level in prostate cancer cells; in addition, the Atypic retinoids 7 can be used for inhibiting the growth and proliferation capacity of the prostate cancer cells LNCaP; in addition, the invention further provides an anti-tumor medicine composition, the anti-tumor medicine composition comprises the Atypic retinoid-7 and Enzalutamide, and the anti-tumor medicine composition can be used for treating the prostatic cancer and has important clinical significance.
Owner:CHIMEDICAL UNIVERSITY

Prostate cancer operation navigation method based on artificial intelligence and fluorescence-like real-time description

The invention discloses a prostatic cancer surgical navigation method based on artificial intelligence and fluorescence-like real-time description, which comprises the following steps: S1, acquiring medical image data of a preoperative prostatic cancer patient, and preprocessing the medical image data; s2, generating dynamic fluorescence image data; s3, constructing a first layer of generative adversarial network; s4, a second generator receives the initial image output by the first generator and generates a refined dynamic tumor boundary image; s5, inputting dynamic fluorescence image data captured in real time into the trained double-layer generative adversarial network in the operation process; and S6, according to the generated refined dynamic tumor boundary image and patient data, dynamically adjusting an operation path according to the real-time change of the tumor morphology. According to the invention, the accuracy and safety of the prostatic cancer operation are obviously improved, and the dynamic tracking of tumors and the real-time adjustment of the operation path in the operation process are ensured.
Owner:ZIGONG NO 4 PEOPLES HOSPITAL

PSMA PET / CT and enhanced MRI multi-modal image registration and fusion method and system

The invention discloses a prostate PSMA PET / CT and enhanced MR multi-modal image registration and fusion method based on deep learning. The method comprises the following steps: preprocessing acquired PSMA PET / CT and enhanced MRI data; a multi-scale multi-stage registration network comprising the semantic gating convolution module and a U-CLSTM module is constructed: the SGC module enhances global perception ability through a V channel, the U-CLSTM module reinforces local feature attention by using a U channel, deformation field iterative optimization is performed in combination with a pyramid structure, and a multi-scale multi-stage registration network comprising the semantic gating convolution module and the U-CLSTM module is constructed; and finally, generating a high-precision registration image through Y channel weighted fusion. According to the method, global information self-adaption and local feature enhancement are combined, the registration precision of a gland anatomical structure and a tumor focus is synchronously improved through a multi-scale pyramid structure, PSMAPT / CT functional metabolism information and MRI anatomical structure information are effectively integrated, the generated three-dimensional fusion image can visually display the spatial position, morphological features and invasion range of a tumor, and the accuracy of the three-dimensional fusion image is improved. A multi-modal image basis with high space consistency is provided for clinical diagnosis, and the diagnosis accuracy of the prostate cancer is remarkably improved.
Owner:SHANGHAI JIAOTONG UNIV

Multi-omic prediction model for metastatic prostate cancer

PendingUS20240379235A1Health-index calculationMedical automated diagnosisSexual hormonesHormone sensitive prostate cancer
Disclosed is a method for predicting a clinical outcome in a metastatic prostate cancer patient based on measurements of multi-omic features of the patient. A weighting model is selected based on the state of the metastatic prostate cancer (a metastatic hormone sensitive prostate cancer (mHSPC) state or a metastatic castrate resistant prostate cancer (mCRPC) state) and on a clinical outcome of interest. The weighting model maps weights to a series of features (including genetic markers and lipid markers) with respect to the clinical outcome of interest. The weights are generated using a machine learning process that utilizes a training dataset that associates the features of multiple historic metastatic prostate cancer patients with recorded clinical outcomes of those patients. A predictive model generates a probability score for the patient indicating the likelihood of occurrence of the clinical outcome of interest.
Owner:UNIV OF UTAH RES FOUND

Prostate cancer and hyperplasia prediction system based on multiple modes and construction method

The invention provides a multi-mode-based prostate cancer and hyperplasia prediction system and a construction method, relates to the technical field of medical image processing, effectively reduces errors possibly introduced by automatic division through precise combination of preliminary division and secondary identification, improves the accuracy and reliability of prostate region identification, and improves the prostate cancer and hyperplasia prediction efficiency. The time of the whole prediction process can be effectively shortened by adopting a parallel computing processing mode, the processing efficiency is improved, the accuracy of feature recognition can be further improved by matching with fusion and screening of multi-modal features, and a good guarantee is provided for high accuracy and high efficiency of prediction results of prostate cancer conditions and bone metastasis conditions of the prostate cancer conditions.
Owner:FUJIAN PROVINCIAL HOSPITAL

Application of marine fungus-derived citrinin derivative cladosporin C in preparation of anti-prostatic cancer drugs

The invention discloses an application of a citrinin derivative cladosporin C derived from marine fungi in preparation of a medicine for resisting prostatic cancer. The structural formula of the compound cladosporin C is as shown in formula (I). The compound cladosporin C is prepared and separated from a fermentation product of a marine fungus Talaromyces sp.SCSIO 41412, and the compound cladosporin C is prepared and separated from the fermentation product of the marine fungus Talaromyces sp.SCSIO 41412. The cladosporin C can inhibit proliferation of PC-3 and 22Rv1 prostate cancer cells, has IC50 values of 6.51 mu M and 9.25 mu M respectively, and can be used for preparing the anti-prostate cancer medicine. Therefore, the cladosporin C disclosed by the invention can be used as a supplementary choice or a drug choice for combined treatment after androgen receptor antagonists such as enzalutamide are resistant to drugs, and has important significance on development of marine drug resources in China. # imgabs0 #
Owner:SOUTH CHINA SEA INST OF OCEANOLOGY CHINESE ACAD OF SCI